Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
All therapeutic advances in cancer immunology are based on our growing understanding of fundamental immunological mechanisms. We approach immunology as a complex system in which many cell populations activate and regulate each other. We believe that the
complexity of the immune system provides many points of intervention for cancer immunotherapy. It is well established in human cancers that the presence of particular immune cell populations – such as activated cytotoxic T cells – strongly correlates
Several labs in the department study the function of T cells at a cellular, molecular, and structural level and are identifying novel targets for enhancing T cell-mediated responses in cancer (Cantor, Wucherpfennig, Novina).